Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shaanxi Micot Technology
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for MT-200605](https://pryzm-maps.s3.us-west-2.amazonaws.com/12current_maps.png)
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Ischemic Stroke|Reperfusion Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MT200605-I-C01 | P1 |
Enrolling by invitation |
Ischemic Stroke |
2024-07-30 |
43% |
CTR20231741 | P1 |
Not yet recruiting |
Reperfusion Injury|Ischemic Stroke |
None |